Why Some Hospitals Won’t Be Able to Comply With Upcoming HIPAA Updates

The first major update to HIPAA in more than a decade will eliminate the distinction between “required” and “addressable” safeguards, making key cybersecurity and physical security measures mandatory for all healthcare providers. This shift will expose gaps in hospitals’ fragmented security systems, though, according to Kumar Sokka, CEO of cybersecurity platform Acre Security. The post…

Read More

Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition

KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angioedema. Ekterly’s tablet formulation offers a dosing edge compared to injectable HAE medications. The post Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition appeared first on MedCity…

Read More

AI-Driven Layoffs In Healthcare: Navigating Legal Risks and Operational Challenges

Layoffs tied to AI adoption will not be uniform; they will vary by sector, job function, and regulatory exposure. Nowhere is this more complex than in healthcare, where legal constraints, patient safety obligations, and labor dynamics intersect with rapid technological change. The post AI-Driven Layoffs In Healthcare: Navigating Legal Risks and Operational Challenges appeared first…

Read More

6 Things to Know About Medtronic’s Cyberattack

Medtronic suffered a cyberattack on its corporate IT systems. The incident highlights growing cybersecurity risks in the medtech sector, with cybergangs increasingly using phishing and other human-engineering tactics to gain access to data. The post 6 Things to Know About Medtronic’s Cyberattack appeared first on MedCity News.

Read More

Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics

Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis. The post Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics appeared first on…

Read More